Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
News|Articles|September 30, 2026
The Psychiatric Pipeline in Review: Quarter 3, 2026
Author(s)Leah Kuntz
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
Advertisement
Advertisement
The third quarter of 2026 had several prominent developments in the psychiatric treatment pipeline. Here, learn more about what percentage of that news was positive vs negative, what disease states were most prominently featured, and what treatments you should keep an eye on.
Related to this article
Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Advertisement
Advertisement